Published August 3, 2026
On April 13, 2026, a Delaware Superior Court judge dismissed more than 80,000 lawsuits filed before December 2025 alleging that the discontinued heartburn drug Zantac (ranitidine) caused cancer. The ruling applies to claims against Boehringer Ingelheim, one of several companies that made or sold ranitidine products over the years, and followed a Delaware Supreme Court decision that tightened the standard for the scientific expert testimony plaintiffs needed to prove Zantac caused their illness. The court found plaintiffs hadn't met that standard, granting summary judgment against them on the core scientific question every case depended on.
Boehringer pointed to nine prior jury trials in which plaintiffs failed to prove their case against the company as consistent with the outcome. It's a significant setback for a large share of the Zantac litigation — but not the end of the line for everyone who believes ranitidine caused their cancer.
The Delaware ruling is specific to cases against Boehringer Ingelheim filed in that state's courts before December 1, 2025. It doesn't reach claims against the other companies that made or sold branded and generic ranitidine — Pfizer, Sanofi, and GSK — many of which remain in active litigation in state courts including Illinois and California. GSK separately settled roughly 93% of its pending U.S. state-court Zantac claims, covering about 80,000 plaintiffs, in a $2.2 billion deal announced in 2024; that settlement is a distinct track from the Delaware dismissal and from claims against the other manufacturers.
In other words, a plaintiff's manufacturer, filing state, and filing date all matter enormously to whether this dismissal affects their case at all.
If you took Zantac or a generic ranitidine product regularly and were later diagnosed with cancer, the Delaware ruling is a reason to get case-specific guidance rather than a reason to assume you have no options — which manufacturer's product you used and where a claim would be filed both affect what comes next. See Atumio's Zantac case page for a free, no-obligation review, or start your case review directly.